1.       Huang S, Yang S, Hincapie-Castillo JM, Ke X, Schelfhout J, Ding H, Sher M, Jones B, Wilson D, Lo-Ciganic W. J Manag Care Spec Pharm, 2022 Oct;28(10-a Suppl):S88 (Poster Presentation at the Academy of Managed Care Pharmacy 2022 annual meeting)

 2.       Lo-Ciganic W, Huang S, Hincapie-Castillo JM, Ke X, Schelhout J, Ding H, Sher M, Wilson D. Characteristics and Trends in Cough Medication Use Among Patients with Chronic Cough in Florida: 2013-2019. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):157 (Poster Presentation at 38th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 3.       Lo-Ciganic W, Yang S, Chang C, Hincapie-Castillo JM, Gellad W, Jones B, Lee J, Huang J,  Wilson D, Reisfield G, Kwoh C, Nguyen K, Delcher C, Harle C, Ge Y, Shorr R, Huang P, Adkins L. Trajectories of Concurrent Opioid and Benzodiazepine Use and Associated Opioid Overdose Risk Among Arizona Medicaid Beneficiaries. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):524-525 (Poster Presentation at 38th International Conference on Pharmacoepidemiology and Therapeutic Risk) 

 4.       Lo-Ciganic W, Chang C, Hincapie-Castillo JM, Park H, Heldermon C, Diaby V, Yang S, Wilson D. Trends and Characteristics Associated with Nonadherence to Antidepressants Among Breast Cancer Survivors with Depression. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):366-367 (Poster Presentation at 38th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 5.       Goodin A, Maguire M, Hincapie-Castillo JM. Buprenorphine Utilization Trends Resulting from Multiple State Insurance Reimbursement Policy Changes: An Exploratory Joinpoint Analysis. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):370-371 (Poster Presentation at 38th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 6.       Figgatt M, Schranz A, Hincapie-Castillo JM, Golightly Y, Marshall S, Dasgupta N. A Review of Algorithms Used to Identify People Who Use Nonmedical or Psychotropic Drugs in Electronic Healthcare Records and Claims Data. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):213 (Poster Presentation at 38th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 7.       *Hernandez-Con P, Park H, Maguire M, Keshwani S, Hincapie-Castillo JM. Prescription Patterns in Patients with Incident Trigeminal Neuralgia. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):47 (Podium Presentation at 38th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 8.       Lewis M, Zhou L, Gellad WF, Hincapie-Castillo JM, Wilkie DJ, Segal R, Wilson DL, Lo-Ciganic W. Geographic Variation of High-risk Prescription Opioid Use Measures Among Disabled Medicare Beneficiaries, 2011-2018. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):50-51 (Podium Presentation at 38th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 9.       Lo-Ciganic W, Hincapie-Castillo JM, Chang C, Jones B, Park H, Heldermon C, Diaby V, Wilson D. The Association Between Trajectories of Prescription Opioid Use and Opioid Overdose Risk Among Nonmetastatic Breast Cancer Survivors. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):51 (Podium Presentation at 38th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 10.   Hincapie-Castillo JM, Lo-Ciganic W, Chang C, Jones B, Park H, Heldermon C, Diaby V, Wilson D. The Association Between Trajectories of Adherence to Endocrine Therapy and the Risk of Breast Cancer Recurrence Among Nonmetastatic Breast Cancer Survivors. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):112-113 (Podium Presentation at 38th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 11.   Hincapie-Castillo JM, Gellad W, Jones B, Lee J, Huang J, Chang C, Wilson D, Reisfield G, Kwoh C, Nguyen K, Delcher C, Harle C, Ge Y, Shorr R, Marcum Z, Yang S, Huang P, Adkins L, Lo-Ciganic W. Dosing Profiles of Opioid and Benzodiazepine Use Associated with Risk of Injurious Falls Among US Medicare Beneficiaries: Group-based Multi-trajectory Models. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):53 (Podium Presentation at 38th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 12.   Lewis M, Zhou L, Gellad WF, Hincapie-Castillo JM, Wilkie DJ, Segal R, Wilson DL, Lo-Ciganic W. HSD125 Geographic Variation of High-Risk Prescription Opioid Use Measures Among Disabled Medicare Beneficiaries, 2011-2018. Value in Health. 2022; 25(7):S501. (Poster Presentation at the 2022 ISPOR Conference)

 13.   Yang S, Hincapie-Castillo JM, Ke X, Schelfhout J, Ding H, Sher M, Wilson DL, Lo-Ciganic W. HSD50 Evaluation of Utilization Patterns of Cough Medications in Ambulatory Care Settings in the United States: 2003-2018. Value in Health. 2022; 25(7):S488-S489. (Poster Presentation at the 2022 ISPOR Conference)

 14.   * Keshwani S, Goodin A, Lo-Ciganic W, Hincapie-Castillo JM. Buprenorphine Use Trends Following Prior Authorization Policy Change for Opioid Use Disorder Treatment in Two State Medicaid Programs, from 2013 to 2020. (Published in conference proceedings, Poster presentation accepted at virtual 2021 Addiction Health Services Research Conference)

 15.   Ravindra N, Faddoul N, Lo-Ciganic W, Hincapie-Castillo JM, Park H, Heldermon CD, Yang S, Wilson DL, Adkins L, Chang C. Association Between Non-Adherence to Endocrine Therapy and the Risk of Recurrence Among Breast Cancer Survivors: A Systematic Literature Review. Pharmacoepidemiol Drug Saf. 2021;30(Suppl. 1):148-149 (Poster at Virtual 37th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 16.   Faddoul N, Ravindra N, Lo-Ciganic W, Hincapie-Castillo JM, Park H, Heldermon CD, Yang S, Wilson DL, Adkins L, Chang C. Opioid Use Patterns Among Non-Metastatic Cancer Survivors: A Systematic Literature Review. Pharmacoepidemiol Drug Saf. 2021;30(Suppl. 1):285 (Poster at Virtual 37th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 17.   Oueini R, Hincapie-Castillo JM, Goodin A, Vouri S. Co-utilization of Opioids and Non-Benzodiazepine Sedative Hypnotics in U.S. Ambulatory Care Visits, 2006 – 2016. Pharmacoepidemiol Drug Saf. 2021;30(Suppl. 1):100-101 (Poster at Virtual 37th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 18.   Yang S, Lipe A, Boren M, Hincapie-Castillo JM, Brown J, Guo J, Park H, Chang C, Wilson DL, Adkins L, Lo-Ciganic W. Trends in the Management of Primary Headache in US Emergency Departments: Analysis of 2007-2018 U.S. National Hospital Ambulatory Medical Care Survey Data. Pharmacoepidemiol Drug Saf. 2021;30(Suppl. 1):378 (Poster at Virtual 37th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 19.   * Keshwani S, Brown J, Lo-Ciganic W, Yang S, Smolinski N, Hincapie-Castillo JM. Trends in Prescribing of Non-Steroidal Anti-Inflammatory Medications in the US Ambulatory Care Setting, 2006-2016. Pharmacoepidemiol Drug Saf. 2021;30(Suppl. 1):377-378 (Poster at Virtual 37th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 20.   Hincapie-Castillo JM, Goodin A, Allen J, Grundman O, Cavanaugh T. A spatiotemporal evaluation of community pharmacy practice experience site placement within diverse patient communities (2016-2020). (Published in conference proceedings, Poster presentation at the 2020 American Association for Colleges of Pharmacy Virtual Annual Meeting)

 21.   * Ourhaan N, Bhagwandass H, Goodin A, Hincapie-Castillo JM. Trends in Utilization of Amphetamine-Containing Medications Following State Level Restriction Laws for Acute Pain Opioid Prescriptions. Value in Health. 2021; 24:S89-S90 (Poster Presentation at the 2021 ISPOR Virtual Conference)

22.   * Staret J, Goodin A, Bhagwandass H, Hincapie-Castillo JM. Changes in Schedule II Opioid Prescriptions Dispensed by Medicaid in Following Acute Pain Opioid Restriction Laws. Value in Health. 2021; 24:S149 (Poster Presentation at the 2021 ISPOR Virtual Conference)

 23.   * Easey T, Vouri SM, Goodin A, Hincapie-Castillo JM, Impact of State Laws Restricting Opioid Prescriptions forAcute Pain on Opioid-Related Overdose Deaths Assessed Via Interrupted Time Series Analyses. Value in Health. 2021; 24:S132-S133 (Poster Presentation at the 2021 ISPOR Virtual Conference)

 24.   Yang S, Boren M, Lipe A, Hincapie-Castillo JM, Joshua DB, Park H, Guo J, Chang C, Wilson DL, Adkins EL, Lo-Ciganic W. Trends and Characteristics in Opioid Analgesic Use for Migraine in US Emergency Departments: Analysis of National Hospital Ambulatory Medical Care Survey 2007-2018 Data. Value in Health. 2021; 24:S168 (Poster Presentation at the 2021 ISPOR Virtual Conference)

 25.   Ravindra N, Faddoul N, Lo-Ciganic W, Hincapie-Castillo JM, Park H, Heldermon CD, Yang S, Wilson DL, Adkins L, Chang C. Association Between Non-adherence to Endocrine Therapy and the Risk of Recurrence among Breast Cancer Survivors: A Systematic Literature Review. Value in Health. 2021; 24:S62 (Poster Presentation at the 2021 ISPOR Virtual Conference)

 26.   Goodin AJ, Hincapie-Castillo JM, Maguire M, Okpeku A, Min J, AG Winterstein. Enhancing Prediction of All-Cause 30-Day Inpatient Psychiatric Facility Readmissions Using Electronic Health Record-Derived Data. (Published in conference proceedings, Poster presentation at Academy Health 2021 Annual Research Meeting)

 27.   * Keshwani S, Grande I, Maguire M, Vouri S, Goodin A, Hincapie-Castillo JM. The effects of the Florida’s Opioid Restriction Law for Acute Pain on the Utilization of Prescription NSAID Medications. (Published in conference proceedings, Poster presentation at virtual 2020 American Academy of Pain Medicine Annual Meeting)

 28.   Oueini R, Hincapie-Castillo JM, Vouri SM. Co-utilization of Opioids and Non-Benzodiazepine Sedative Hypnotics in US Ambulatory Care Visits, 2006–2016. (Published in conference proceedings; Poster presentation at the 2020 American College of Clinical Pharmacy Annual Meeting)

 29.   * Easey T, Smith K, Chirino A,Hernandez C, Moorman-Li R, Goodin A, Vouri S, Hincapie-Castillo JM. Comparing the Current Status of State Laws of Opioid Prescribing Restrictions in the United States. Addict Sci Clin Pract 2020, 15(Suppl 2):A91 (Poster presentation at virtual 2019 Addiction Health Services Research Conference)

 30.   Valdes I, Possinger M, Hincapie-Castillo JM, Goodin A, Dewar M, Sumfest J, Vouri S. Changes in Opioid Utilization by Provider Type Following a Days’ Supply Restriction Policy. Addict Sci Clin Pract 2020, 15(Suppl 2):A90  (Poster presentation at virtual 2019 Addiction Health Services Research Conference)

 31.   Shen Y, Bhagwandass H, Branchcomb T, Galvez S, Grande I, Hollmann J, Lessing J, Mollanazar M, Ourhaan N, Oueini R, Sasser M, Valdes I, Jadubans A, Vouri S, Hincapie-Castillo JM, Adkins L, Goodin A. Chronic Opioid Therapy: A Scoping Literature Review on Evolving Clinical and Scientific Definitions. Addict Sci Clin Pract 2020, 15(Suppl 2):A113  (Poster presentation at virtual 2019 Addiction Health Services Research Conference) 

 32.   Shen Y, Hincapie-Castillo JM, Vouri S, Dewar M, Sumfest J, Goodin A. Prescription Patterns of Adjuvant Medications Following Opioid Supply Restriction Law in Florida: An Interrupted Time Series Analysis. Addict Sci Clin Pract 2020, 15(Suppl 2):A12 (Poster presentation at virtual 2019 Addiction Health Services Research Conference)

33.   Hincapie-Castillo JM, Goodin A, Tadrous M, Dal Pan G. Methods to Evaluate the Effects of Policy Changes During the Opioid Crisis. Pharmacoepidemiol Drug Saf. 2020;29(Suppl. 3):153 (Symposium at Virtual 36th International Conference on Pharmacoepidemiology and Therapeutic Risk)

 34.   Lo-Ciganic W, Wang T, Ge Y, Jones B, Huang J, Reisfield G, Lee J, Kwoh K, Hincapie-Castillo JM, Delcher C, Chang CY, Wilson D, Gellad W. Association between Dose and Duration Patterns of Opioid and Benzodiazepine Use and Risk of Overdose Among US Medicare Beneficiaries: A Group-Based Multi-Trajectory Model. Pharmacoepidemiol Drug Saf. 2020;29(Suppl. 3):5 (Podium presentation at Virtual 36th International Conference on Pharmacoepidemiology and Therapeutic Risk Management)

 35.   Chang C, Hincapie-Castillo JM, Wilson DL, Lo-Ciganic W Trends and Patient Characteristics in Concurrent Use of Opioids with High-risk Medications among Arizona Medicaid Beneficiaries, 2011-2017. Pharmacoepidemiol Drug Saf. 2020;29(Suppl. 3):274 (Poster presentation at Virtual 36th International Conference on Pharmacoepidemiology and Therapeutic Risk Management)

 36.   Yang S, Hincapie-Castillo JM, Chang C, Wilson DL, Lo-Ciganic W. Trends and Characteristics in Cough Prescription Use in Ambulatory Care Settings in the United States: 2003-2016. Pharmacoepidemiol Drug Saf. 2020;29(Suppl. 3):253 (Poster presentation at Virtual 36th International Conference on Pharmacoepidemiology and Therapeutic Risk Management)

 37.   Tran P, Antonelli P, Hincapie-Castillo JM, Winterstein A. Impact of the Food and Drug Administration Safety Warnings and Removal of Indications for Use of Oral Quinolones. Pharmacoepidemiol Drug Saf. 2020;29(Suppl. 3):151-152 (Podium presentation at Virtual 36th International Conference on Pharmacoepidemiology and Therapeutic Risk Management)

 38.   Goodin A, Huang J, Park H, Hincapie-Castillo JM, Brown J, Costales B(g), Wilson D, Lo-Ciganic W. Changes in Prevalence of High-Risk Opioid Use Quality Measures in Arizona, 2011-2018. (Published in conference proceedings; Poster presentation at the 2020 Virtual Annual Research Meeting of AcademyHealth)

 39.   Jugl S, Okpeku A Costales B, Morris E, Alipour-Harris G, Hincapie-Castillo JM, Stetten N, Sajdeya R, Keshwani S, Joseph V, Zhang Y, Shen Y, Adkins L, Goodin A. A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the United States from 2016 to 2019. Cannabis. 2021, 4(1), 15-16 (Poster presentation at the 2020 Research Society of Marijuana virtual meeting)

 40.   Hincapie-Castillo JM, Unigwe I, Goodin A, Vouri S. Enhancing Active Learning of Root Cause Analysis: An Immersive Medication Error Experience from Multiple Perspectives. American Journal of Pharmaceutical Education. 2020; 84(6). (Poster presentation at the 2020 American Association for Colleges of Pharmacy Virtual Annual Meeting)

 41.   Goodin A, Hincapie-Castillo JM, Vouri S. Pragmatic Model for PharmD Student Engagement in Social and Administrative Pharmacy Research: UF Research Workgroup. American Journal of Pharmaceutical Education. 2020; 84(6). (Poster presentation at the 2020 American Association for Colleges of Pharmacy Virtual Annual Meeting)

 42.   * Tasmim K,  Goodin A, Lopez-Quintero C, Park H, Mora J, Lo-Ciganic W, Hincapie-Castillo JM. Increases in County-Level Opioid Prescribing in the United States despite National Declining Rates, 2012-2017. (Published in conference proceedings; Poster presentation at the 2020 Virtual Scientific Meeting of the College on Problems of Drug Dependence)

 43.   Hincapie-Castillo JM, Goodin A, Vouri S, Lo-Ciganic W, Park H. PDG33 Changes in Schedule II Oral Opioid Volume Dispensed in a Private Payer Following Florida’s Acute Pain Opioid Restriction Law. Value in Health. 2020; 23:S135 (Poster presentation at the 2020 ISPOR Virtual Conference)

 44.   Lo-Ciganic W, Wang T, Ge Y, Jones B, Huang J, Reisfield GM, Lee JK, Kwoh CK, Hincapie-Castillo JM, Delcher C, Chang CY, Wilson D, Gellad. WPMH26 Association between Dose and Duration Patterns of Opioid and Benzodiazepine Use and Risk of Overdose Among US Medicare Beneficiaries: A Group-Based Multi-Trajectory Model. Value in Health. 2020; 23:                                       S204-S205 (Poster Presentation at the 2020 ISPOR Virtual Conference)

 45.   Chang C-Y, Hincapie-Castillo JM, Wilson DL, Lo-Ciganic W. Evaluation of concurrent use of opioids with high-risk medications among Arizona Medicaid beneficiaries: cross-sectional analysis from 2011 to 2017. Pharmacoepidemiol Drug Saf. 2020;29(Suppl. 3):643 (Poster presentation at the 2020 Mid-Year ISPE meeting [canceled due to COVID-19])

 46.   Shen Y, Vouri S, Hincapie-Castillo JM, Goodin A. Prescription Opioid Patterns Following Supply Restriction Policy among Patients Receiving Chronic Opioid Therapy: An Interrupted Time Series Analysis. Pharmacoepidemiol Drug Saf. 2020;29(Suppl. 3):647 (Poster presentation at the 2020 Mid-Year ISPE meeting [canceled due to COVID-19])

 47.   Lemon S, Brokenshire S, Staley B, Voils A, Hincapie-Castillo JM. 119: Impact of Injectable Opioid Restrictions on Opioid Consumption during a Critical Drug Shortage. Crit Care Med. 2020 Jan;48(1):42. (Poster presentation at the 2020 Critical Care Congress, Orlando, FL)

 48.   Hincapie-Castillo JM, Goodin A, Silken U, Possinger M, Vouri S. Changes in Opioid Utilization Following Florida’s Acute Pain Restriction Policy. In: Garets M, Archer S, Kitchens C, Cochran G, Gordon AJ. The 2019 Addiction Health Services Research Conference: Insights, review, and abstracts. Subst Abus. 2019;40(4):469-472 (Supp 113) (Podium presentation 2019 Addiction Health Services Research Conference, Park City, UT)

 49.   Goodin A, Huang J, Park H, Skvarla D, Hincapie-Castillo JM, Lo-Ciganic W. Controlled Substance Prescription Utilization Trends in Arizona from 2011-2016, by Prescription Class. In: Garets M, Archer S, Kitchens C, Cochran G, Gordon AJ. The 2019 Addiction Health Services Research Conference: Insights, review, and abstracts. Subst Abus. 2019;40(4):469-472 (Supp 113). (Podium presentation at 2019 Addiction Health Services Research Conference, Park City, UT)

 50.   Usmani S, Hollmann J, Ourhaan N, Oueini R, Bhagwandass H, Goodin A, Hincapie-Castillo JM, Vouri S. Effects of Hydrocodone Rescheduling on Opioid Prescribing Outcomes: A Systematic Review. In: Garets M, Archer S, Kitchens C, Cochran G, Gordon AJ. The 2019 Addiction Health Services Research Conference: Insights, review, and abstracts. Subst Abus. 2019;40(4):469-472 (Supp 113). (Poster presentation at 2019 Addiction Health Services Research Conference, Park City, UT)

 51.   Hincapie-Castillo JM, Antonelli P, Winterstein AG. Use of Joinpoint regression in drug utilization research: Post-tonsillectomy codeine use in pediatrics, United States (2005-2016). Pharmacoepidemiol Drug Saf. 2019; 28(Suppl. 2):250-251. (Poster presentation at the 35th International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA)

52.   Sarayani A, Albogami Y, Elkhider M, Hincapie-Castillo JM, Brumback B, Winterstein AG. Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate. Pharmacoepidemiol Drug Saf. 2019; 28(Suppl. 2):222. (Podium presentation at the 35th International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA)

 53.   Hincapie-Castillo JM, Guo Y, Silver NL, Xiao H. Spatial analysis of late-stage oropharyngeal cancer diagnosis in Florida: Hierarchical models and geographically-weighted regression. Cancer Res 2018;78(13 Suppl):Abstract number 1202. (Poster presentation at 2018 American Association of Cancer Research Annual Meeting, Chicago, IL)

 54.   Liu, X, Hincapie-Castillo JM, Zhu Y, Bussing R, Winterstein AG. Prevalence of Concomitant Use of Psychotropic Drugs with Severe or Major Drug-Drug Interactions in Children and Adults with Psychotropic Therapy. Pharmacoepi Drug Saf 2017; 26(Suppl. 2):334. (Poster presentation at 33rd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Montreal, CA)

 55.   Hincapie-Castillo JM, Smith A. Abstract Selection Process for the 2017 International Society for Pharmacoepidemiology Midyear Meeting Pharmacoepi Drug Saf 2017; 26(Suppl. 2):492. (Poster presentation at 33rd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Montreal, CA)

 56.   Hincapie-Castillo JM, Staley B, Henriksen C, Lipori G, Winterstein AG. Development of a Predictive Model for Uncontrolled Post-Operative Pain in the Inpatient Setting Using Electronic Health Record Data. (Published in conference proceedings; Podium presentation at the 2017 Mid-Year ISPE meeting, London, UK)

 57.   Hincapie-Castillo JM, Henriksen C, Staley B, Saidi A, Lipori G, Winterstein AG Development of a Predictive Model for Drug-induced QT Prolongation in the Inpatient Setting Using Electronic Health Record Data. Pharmacoepi Drug Saf 2016; 25(Suppl. 3):492. (Podium presentation at 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, IE)

58.   Soria-Saucedo R, Liu X, Hincapie-Castillo JM, Winterstein AG. Prevalence, Time Trends and Utilization Patterns of Psychotropic Polypharmacy: Evidence from Children and Adolescent Medicaid Beneficiaries, 1999-2010. Pharmacoepi Drug Saf 2016; 25(Suppl. 3):668. (Poster presentation at 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, IE)

 59.   Soria-Saucedo R, Liu X, Hincapie-Castillo JM, Winterstein AG. Prevalence, Time Trends and Utilization Patterns of Psychotropic Polypharmacy: Evidence from Adult Medicaid Beneficiaries, 1999-2010. Pharmacoepi Drug Saf 2016; 25(Suppl. 3):668. (Poster presentation at 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, IE)

 60.   Soria-Saucedo R, Liu X, Hincapie-Castillo J, Bussing R, Winterstein AG. Prevalence, time trends and utilization patterns of psychotropic polypharmacy: Evidence from children and adolescent Medicaid beneficiaries, 1999-2010. (Published in conference proceedings, Poster presentation at the 2016 Annual Research Meeting Academy Health, Boston, MA)

 61.   Bussing R, Liu X, Hincapie-Castillo JM, Winterstein AG. Psychotropic Polypharmacy Patterns in Medicaid Recipients: Trends and Concerns. (Published in conference proceedings, Poster presentation at the 2015 Annual Meeting of American Academy of Child and Adolescent Psychiatry, San Antonio, TX)

 62.   Knox CA, Hincapie-Castillo JM, Winterstein AG. Validity of Delivery Outcomes Within the Medicaid Analytic eXtract (MAX) Database. Pharmacoepi Drug Saf 2015; 24:14. (Podium presentation at 31st International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA)

 63.   Hincapie-Castillo JM. Prescription Drug Monitoring Program and Drug Arrests in Florida: Spatial Analysis. Pharmacoepi Drug Saf 2015; 24:69. (Poster presentation at 31st International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA)

 64.   Winterstein AG, Hincapie-Castillo JM, Xu D, Liu W, Antonelli PJ. Ototopical Neomycin Exposure in Children with Non-Intact Tympanic Membranes. (Published in conference proceedings, Poster presentation at the 2012 American Laryngological Rhinological and Otological Society, Miami, FL)